Characteristic | Subjects |
Males/females | 175 (72.9)/60 (25) |
Data not available | 5(2.1) |
Age range yrs | |
<30 | 7 (2.9) |
30–39 | 4 (1.7) |
40–49 | 17 (7.1) |
50–59 | 55 (22.9) |
60–69 | 71 (29.6) |
>70 | 71 (29.6) |
Not available | 15 (6.3) |
BMI kg·m−2 | |
<18.5 | 7 (2.9) |
18.5–24.9 | 77 (32.1) |
25.0–29.9 | 66 (27.5) |
>30 | 25 (10.4) |
Not available | 65 (25.5) |
Never-smokers | 38 (15.8) |
Former smokers | 99 (41.3) |
Current smokers | 85 (35.4) |
Tobacco consumption unknown | 18 (7.5) |
Tobacco consumption pack-yrs | 59.1±64.4 |
Patients with COPD | 74 (30.8) |
GOLD stage 1 | 9 (12.2) |
GOLD stage 2 | 31 (41.9) |
GOLD stage 3 | 11 (14.9) |
GOLD stage 4 | 0 (0.0) |
Not classified | 23 (31.0) |
Cystic fibrosis | 1 (0.4) |
Asthma | 5 (2.1) |
Diffuse interstitial lung disease | 4 (1.7) |
Bronchiectasis | 4 (1.7) |
α1-antitrypsin deficiency | 1 (0.4) |
Sleep apnoea | 12 (5.0) |
No known respiratory comorbidities | 110 (45.8) |
Surgery for lung cancer yes/no | 185 (77.1)/21 (8.8) |
Data not available | 34 (14.2) |
Data are presented as n (%) or mean±sd, unless otherwise stated. n = 240. BMI: body mass index; COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease.